The Medicus Pharma Ltd. (NASDAQ: MDCX) SEC filings page on Stock Titan provides direct access to the company’s U.S. regulatory disclosures, including registration statements, current reports and financing-related documents. Medicus is an Ontario-incorporated biotech and life sciences company focused on SkinJect™, a doxorubicin microneedle array for basal cell carcinoma, and Teverelix, a long-acting GnRH antagonist for prostate and urologic indications.
Key filing types for MDCX include registration statements on Form S-1, which describe offerings and resale registrations tied to standby equity purchase agreements, warrant exercises and acquisition-related consideration shares. These S-1 filings outline the company’s business, risk factors, pipeline programs and capital structure in detail. Investors can review sections covering the SkinJect™ and Teverelix clinical programs, as well as the terms of equity facilities with counterparties such as YA II PN, Ltd. (Yorkville) and Armistice Capital Master Fund Ltd.
Current reports on Form 8-K document material events such as the acquisition of Antev Limited, warrant inducement agreements, new debenture financings, non-binding memoranda of understanding, and updates on clinical and regulatory milestones. For example, 8-K filings describe the Antev transaction that added Teverelix to the pipeline, the terms of a debenture issued to Yorkville, and inducement arrangements for the exercise of outstanding warrants.
Through this page, users can also monitor unregistered sales of equity securities disclosed under Item 3.02 of Form 8-K, which provide insight into how Medicus funds its clinical development activities. While insider Form 4 reports are not summarized in the provided data, Stock Titan’s platform is designed to surface such ownership changes when available.
How Stock Titan helps
Stock Titan enhances these filings with AI-powered summaries that explain complex documents in plain language, highlight key terms in S-1 and 8-K filings, and point out items relevant to Medicus’s SkinJect™ and Teverelix programs. Real-time EDGAR updates mean new MDCX filings appear quickly, and investors can use this page to track registration statements, financing terms and other regulatory disclosures without reading every page of each filing.
Medicus Pharma Ltd. registers 3,245,595 common shares issuable upon exercise of warrants. This prospectus supplement (dated May 14, 2026) amends the existing prospectus and incorporates the Company's Form 10-Q for the quarter ended March 31, 2026. The supplement records the number of common shares that may be issued if outstanding warrants are exercised and updates investors with interim financials.
The attached Form 10-Q shows 56,658,164 common shares issued and outstanding as of May 7, 2026, cash of $6,365,624 at March 31, 2026, a three-month net loss of $9,042,311, and a working capital balance of $1,328,773. Management discloses substantial doubt about the Company's ability to continue as a going concern within one year.
Medicus Pharma Ltd. reports first-quarter 2026 results, with a net loss of $9.0M and no revenue as it advances its drug pipeline. Operating expenses rose sharply, driven by higher general and administrative spending and increased research and development, including work on Teverelix and SkinJect.
Cash and cash equivalents were $6.4M as of March 31, 2026, after using $9.0M in operating cash during the quarter and raising equity through a standby equity purchase agreement and at-the-market sales. Management discloses substantial doubt about the company’s ability to continue as a going concern.
The company expanded its at-the-market program and continued to rely on Yorkville-financed debentures and equity facilities, while also reporting positive Phase 2 data for its SkinJect microneedle therapy and FDA clearance to begin a Phase 2b study of Teverelix in advanced prostate cancer.
Medicus Pharma Ltd. Schedule 13G/A discloses that Ajay Raju (including related entities) beneficially owns 2,031,250 Common Shares, representing 3.7% of the class. The filing states 55,164,465 Common Shares outstanding as of April 30, 2026.
The holding consists of 2,000,000 shares held of record by 215 Capital Togo PHL Fund I, LP plus 31,250 shares underlying exercisable options. Voting and dispositive power is reported via Togo PHL Management LLC and Ajay Raju as managing member.
Medicus Pharma Ltd. is asking shareholders to approve several items at its June 3, 2026 annual and special meeting, including reappointing KPMG LLP as auditor, electing nine directors, and authorizing a share consolidation of up to 50 old common shares for one new share.
The company has 55,164,465 common shares outstanding as of the April 30, 2026 record date and recently received a Nasdaq notice because its share price closed at $0.28, below the $1.00 minimum bid requirement. The board views a potential share consolidation as a tool to help regain compliance and broaden investor appeal, while noting risks that higher prices or continued listing are not assured.
Medicus Pharma Ltd. files a prospectus supplement to register 3,245,595 common shares issuable upon the exercise of outstanding public warrants. The supplement attaches Amendment No. 1 to the 2025 Form 10-K, which adds Part III disclosures including director and executive officer biographies, board and committee composition, executive compensation tables, and governance policies.
The prospectus notes the Public Warrants carry a $4.64 exercise price and expire November 15, 2029; last reported April 28, 2026 prices were $0.30 per common share and $0.7199 per Public Warrant. Shares outstanding were 41,818,092 as of April 15, 2026.
Medicus Pharma Ltd. filed Amendment No. 1 to its annual report for the year ended December 31, 2025 to add detailed Part III information on directors, executive officers, governance and compensation. The filing confirms a nine‑member board with six standing committees and extensive biographies for each director and senior executive.
The company reports an aggregate market value of non‑affiliate common shares of approximately $28.3 million as of June 30, 2025, and 41,818,092 common shares outstanding as of April 15, 2026. Compensation tables disclose 2025 pay for four named executive officers, including salary, option awards and other compensation, along with option holdings and vesting values.
Medicus Pharma Ltd. filed a Prospectus Supplement No. 1 and attached a Form 8-K to register 3,245,595 common shares issuable upon the exercise of warrants. The supplement reflects an ATM Upsize: the company amended its Equity Distribution Agreement to permit up to $50,000,000 of at-the-market sales and states it has raised approximately $11.5 million under the ATM Offering Program. The filing discloses last reported sales prices of the common shares at $0.3321 and Public Warrants at $0.2901. The company also received Nasdaq notice for noncompliance with the minimum $1.00 bid-price rule and has until October 19, 2026 to regain compliance.
Medicus Pharma Ltd. amended its Equity Distribution Agreement with Maxim Group and Yorkville Securities to expand its at-the-market stock sales program from $15,349,674 to up to $50,000,000. The company has already raised about $11.5 million under this program.
Medicus also received a Nasdaq notice that its shares traded below $1.00 for 30 consecutive business days, putting it out of compliance with Nasdaq’s minimum bid price rule. The company has 180 days, until October 19, 2026, for its closing bid to reach at least $1.00 for 10 straight business days to regain compliance.
MDCX amends its prospectus supplement to offer common shares having an aggregate offering price of up to $50,000,000 under an amended equity distribution agreement dated April 23, 2026. The Sales Agreement names Maxim Group LLC and Yorkville Securities, LLC as Agents. The company’s common shares trade on Nasdaq under MDCX; the prospectus cites a closing share price of $0.339 and Public Warrants closing at $0.2901 as of April 22, 2026.